Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AbbVie files sNDA to FDA for chronic graft versus host disease therapy
AbbVie submits sNDA and NDA to FDA for Imbruvica to treat chronic graft versus host disease (cGVHD) in paediatric patients. Credit: AbbVie Inc. North Chicago, Illinois, U.S.A.
AbbVie submits sNDA and NDA to FDA for Imbruvica to treat chronic graft versus host disease (cGVHD) in paediatric patients. Credit: AbbVie Inc. North Chicago, Illinois, U.S.A.